secwatch.observer — SEC 8-K summary
======================================

Issuer:     Glucotrack, Inc. (GCTK)
CIK:        0001506983
Form:       8-K
Filed at:   2025-03-19T23:59:59+00:00
Accession:  0001493152-25-010873
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Glucotrack to present first-in-human CBGM trial data at ATTD 2025 conference in Amsterdam
--------------------------------------------------------------------------------

- Safety and performance data from first-in-human trial of implantable CBGM system to be presented at ATTD conference, March 19-22, 2025.
- Device measures glucose directly from blood, not interstitial fluid, with no on-body wearables, designed for 3-year continuous monitoring.
- Trial is an early feasibility study in adults with diabetes; results support advancement to chronic implant study.
- CEO Paul Goode highlights potentially transformative advancement in diabetes management.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506983/000149315225010873/0001493152-25-010873-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506983/000149315225010873/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-010873

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer